MG patients studied in the validation cohort.

<p>M = male; F = female; No  =  No treatment/No thymectomy; Cort  =  corticosteroids; Other immunosuppressors =  OI; Yes  =  Thymectomy.</p

Effect of thymectomy on miRNAs levels in the validation cohort.

<p>YES  =  thymectomyzed MG patient; NO  =  not thymectomyzed MG patient.</p

Effect of immunosuppressors treatment on miRNAs levels in the validation cohort.

<p>NO  =  non-treated; Cort  =  patient treated with steroids; Cort + OI  =  patient treated with steroids + other immunosuppressor agent; OI  =  patient treated with immunosuppressor agents other than steroids.</p

Unsupervised HeatMap showing deltaCt values of the miRNA in differential levels between MG patients and controls in the discovery cohort.

<p>Delta Ct value is the difference between Ct value of the target miRNA minus Ct value of the reference small RNAs. The scale at top indicates high delta Ct values (in red shades) and low delta Ct values (in green shades). All miRNAs with a p adjusted value <0.05 are shown. Early onset MG (green), late onset MG (red), thymoma MG (blue) and healthy controls (purple).</p

miR15b, miR122, miR140-3p, miR185, miR192, miR20b and miR885-5p show low levels in sera of MG patients.

<p>No differences were found for miR375. Graphs show relative quantification of the miRNAs in the 3; EOMG  =  early onset MG; late onset MG; thymoma  =  thymoma MG; CTRL  =  healthy controls; *P<0.05; **P<0.01.</p

Subjects analyzed in the discovery cohort.

<p>M = male; F =  female.</p

Additional file 1: Figure S1. of RIG-I expression in perifascicular myofibers is a reliable biomarker of dermatomyositis

Controls used in the study to assess the specificity of the RIG-I antibody. RIG-I antibody was incubated in non-transfected HEK293 cells (left) and in HEK293 cells transfected with the constitutive expression vector pCMV-RIG-I (right). Positivity was only observed in those cells transfected with pCMV-RIG-I. Original magnification × 400. (TIF 3652 kb